Horizon Pharma plc Announces Waiver of Financing Proceeds Condition - Seite 3
Additional Information and Where to Find It
This communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of Hyperion common stock or
any other securities. On April 9, 2015, Horizon Pharma plc filed a tender offer statement on Schedule TO with the SEC and, on the same date, a Solicitation/ Recommendation Statement on a
Schedule 14D-9 was filed with the SEC by Hyperion. The Offer to Purchase shares of Hyperion common stock will only be made pursuant to the offer to purchase, the letter of transmittal and
related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT, AS FILED AND AS IT MAY BE AMENDED FROM TIME TO TIME, AND THE
SOLICITATION/ RECOMMENDATION STATEMENT, AS FILED AND AS MAY BE AMENDED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION REGARDING THE TENDER OFFER. Investors and security holders
may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to Georgeson Inc., the
Information Agent for the tender offer, at (866) 856-2826.
Lesen Sie auch
Contacts:
Company:
Geoff Curtis
Group Vice President, Corporate Communications
Email Contact
International Media:
Ray Gordon
Gordon MRM
Email Contact